Project description
Innovative bioengineered skin grafts for transplantation
Standard of care split-thickness skin autografting procedure for the treatment of skin wounds often leaves patients with scars. After transplantation, the lack of dermis in the transplant induces a quick body reaction to create scar tissue and activate contraction to reduce the wound area. Contraction is characterised by skin constriction that results in additional scarring and functional limitations. The Swiss company CUTISS invented and developed personalised, bioengineered human skin graft technology to produce large quantities originating from a stamp-sized skin biopsy of the patient. The dermo-epidermal structure of the novel autografts will result in minimal scarring after transplantation. The EU-funded denovoSkin project aims to finalise a development plan in regards to the clinical validation of the product and its industrialisation.
Fields of science
Programme(s)
- H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies Main Programme
- H2020-EU.2.1.5. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing
- H2020-EU.2.1.3. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials
- H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
8006 Zurich
Switzerland
See on map